Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Age-related macular degeneration (AMD) also known as macular degeneration is a condition, which results in loss of central vision caused due to the thinning of the macula of the retina. Age-related macular degeneration typically occurs in the geriatric population and can cause permanent vision loss in people aged 60 years and above. Age-related macular degeneration is of two types; dry age-related macular degeneration (Dry AMD) and wet age-related macular degeneration (wet AMD). Dry age-related macular degeneration is a common form of macular degeneration, where the macula gets thinner with age and leads to loss of central vision. There is no treatment available for dry age-related macular degeneration. Wet age-related macular degeneration is less common, where growth of abnormal blood vessels is observed under the retina. Wet age-related macular degeneration can be managed through anti-vascular endothelial growth factor (anti-VEGF) injections.

The North America & Europe age-related macular degeneration therapeutics market is estimated to be valued at US$ 9,958.7 million in 2020 and is expected to exhibit a CAGR of 6.1% during the forecast period (2020-2027).

Figure 1. North America & Europe Age-related Macular Degeneration Therapeutics Market Share (%) in Terms of Value, By Region, 2020

North America & Europe Age-related Macular Degeneration Therapeutics  | Coherent Market Insights

The increasing prevalence of age-related macular degeneration is expected to propel the market growth during the forecast period

The increasing prevalence of age-related macular degeneration is expected to drive growth of the age-related macular degeneration therapeutics market. For instance, according to The International Agency for the Prevention of Blindness (IAPB), around 5% blindness across the globe is caused by age-related macular degeneration (AMD). Moreover, according to an article published in the BrightFocus Foundation in January 2019, it is expected that around 196 million people across the globe will have age-related macular degeneration in 2020 and the number will increase to 288 million in 2040.

request-sample

North America & Europe Age-related Macular Degeneration Therapeutics Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 9,958.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 6.1% 2027 Value Projection: US$ 15,122.8 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Segments covered:
  • By Disease Type: Dry AMD, Wet AMD.
  • By Drug Type: Aflibercept (Eylea), Ranibizumab (Lucentis), Bevacizumab (Avastin), Pegaptanib (Macugen), Verteporfin (Visudyne), Brolucizumab (Beovu), Supplements, Others.
  • By Disease Type: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies.
Companies covered:

Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.

Growth Drivers:
  • The increasing prevalence of age-related macular degeneration
  • The increasing number of product launches and approvals
  • Frequent acquisitions and agreements among players
Restraints & Challenges:
  • Availability of alternative treatment options

Figure 2. North America & Europe Age-related Macular Degeneration Therapeutics Market Share (%), by Disease Type, 2020

North America & Europe Age-related Macular Degeneration Therapeutics  | Coherent Market Insights

The approval and launch of age-related macular degeneration therapeutics is expected to drive the market growth during the forecast period

Approval and launch of new age-related macular degeneration therapeutics products by regulatory authorities is expected to drive the market growth during the forecast period. For instance, in October 2019, Novartis received the U.S. Food and Drug Administration (FDA) approval for its Beovu (brolucizumab) injection for treatment of wet age-related macular degeneration (AMD).

North America & Europe Age-related Macular Degeneration Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic has impacted the overall ophthalmology market in key regions such as North America and Europe. After a formal declaration by the World Health Organization (WHO) on March 11, 2020, COVID-19 pandemic has been declared a public health emergency. With the increasing number of COVID-19 cases in the U.S., on March 18, 2020, the American Academy of Ophthalmology, following advice from the US Surgeon General and the Centers for Disease Control and Prevention, issued the guidelines on COVID-19. According to the guidelines, it is necessary for all ophthalmologists to cease their practice, and are allowed to provide any treatment or assistance to urgent or emergent cases.

Age-related Macular Degeneration Therapeutics Market Restraints:

However, availability of alternate treatments for age-related macular degeneration such as photodynamic therapy, photocoagulation, and low vision rehabilitation is likely to hinder the growth of age-related macular degeneration therapeutics market.

Age-related macular degeneration is one of the most common causes of blindness among the elderly population. The geriatric population is highly susceptible to different types of age-related diseases such as diabetes, renal insufficiency, arthritis, and macular degeneration. According to an article published in the BrightFocus Foundation in January 2019, the risk of getting affected by advanced age-related macular degeneration for people of age group of 50-59 is 2%, whereas it is around 30% among those who are over the age of 75 years. Hence, the high risk of age-related macular degeneration in geriatric population is anticipated to drive the growth of age-related macular degeneration therapeutics market during the forecast period.

Market Dynamics

Majority of pharmaceutical manufacturers operating in the North America & Europe age-related macular degeneration treatment market are engaged in adoption of inorganic growth strategies such as collaborations, partnerships, and acquisitions to strengthen their market share. These strategies have enabled market players to develop new drugs for treating AMD and enhance their existing portfolio of retinal products. For instance, in January 2020, Exonate, an early stage biotechnology company, collaborated with Janssen Pharmaceuticals, Inc., a pharmaceutical companies of Johnson & Johnson, to develop an eye drop treatment for retinal vascular diseases such as wet age-related macular degeneration treatment and diabetic macular oedema (DMO by using mRNA targeted therapies).

Key features of the study:

  • This report provides in-depth analysis of the North America & Europe age-related macular degeneration therapeutics market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the North America & Europe age-related macular degeneration therapeutics market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche AG, Pfizer, Inc., and Valeant Pharmaceuticals International, Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, type up-gradation, market expansion, and marketing tactics
  • The North America & Europe age-related macular degeneration therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the North America & Europe age-related macular degeneration therapeutics market.

Detailed Segmentation:

  • North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type:
    • Dry AMD
    • Wet AMD
  • North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type:
    • Aflibercept (Eylea)
    • Ranibizumab (Lucentis)
    • Bevacizumab (Avastin)
    • Pegaptanib (Macugen)
    • Verteporfin (Visudyne)
    • Brolucizumab (Beovu)
    • Supplements
    • Others
  • North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region:
    • North America
      • By Disease Type:
        • Dry AMD
        • Wet AMD
      • By Drug Type
        • Aflibercept (Eylea)
        • Ranibizumab (Lucentis)
        • Bevacizumab (Avastin)
        • Pegaptanib (Macugen)
        • Verteporfin (Visudyne)
        • Brolucizumab (Beovu)
        • Supplements
        • Others  
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Disease Type:
        • Dry AMD
        • Wet AMD
      • By Drug Type
        • Aflibercept (Eylea)
        • Ranibizumab (Lucentis)
        • Bevacizumab (Avastin)
        • Pegaptanib (Macugen)
        • Verteporfin (Visudyne)
        • Brolucizumab (Beovu)
        • Supplements
        • Others  
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
  • Company Profiles
    • Novartis AG*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • Bayer AG
    • Bausch Health Companies Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Hoffmann-La Roche AG
    • Pfizer, Inc.
    • Valeant Pharmaceuticals International, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Disease Type
      • Market Snippet, By Drug Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. North America & Europe Age-related Macular Degeneration Therapeutics Market – Impact of Coronavirus (Covid-19) Pandemic
    • Impact assessment
    • Pre COVID-19 Market Scenario
    • Post COVID-19 Market Scenario
    • Government measures to combat COVID-19
  5. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Disease Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Dry AMD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Wet AMD
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Drug Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Aflibercept (Eylea)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ranibizumab (Lucentis)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bevacizumab (Avastin)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Pegaptanib (Macugen)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Verteporfin (Visudyne)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Brolucizumab (Beovu)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Supplements
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Distribution Channel, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. North America & Europe Age-related Macular Degeneration Therapeutics Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Disease Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Drug Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Novartis AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bausch Health Companies Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Regeneron Pharmaceuticals, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche AG
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Valeant Pharmaceuticals International, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 46 market data tables and 37 figures on "Age-related Macular Degeneration Therapeutics Market” – North America & Europe forecast to 2027

Frequently Asked Questions

The North America & Europe age-related macular degeneration therapeutics market size is estimated to be valued at US$ 9,958.7 million in 2020 and is expected to exhibit a CAGR of 6.1% between 2020 and 2027.
The increasing prevalence of cardiovascular diseases and the rising number of acquisitions and agreements by market players are driving the age-related macular degeneration therapeutics market growth.
The Dry AMD segment is expected to hold major market share in 2020 owing to the increasing number of research and development activities by market players.
North America age-related macular degeneration therapeutics market generated highest revenue share in 2019.
Major factors hampering growth of the market are the availability of alternative treatment options.
Major players operating in the North America & Europe Age-related Macular Degeneration Therapeutics market are Novartis AG, Bayer AG, Bausch Health Companies Inc., Regeneron Pharmaceuticals, and others.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner